Excision repair cross complementation group 1 is a chemotherapy-tolerating gene in cisplatin-based treatment for non-small cell lung cancer

Wang,Shoufeng; Pan,Hong; Liu,Desen; Mao,Naiquan; Zuo,Chuantian; Li,Li; Xie,Tong; Huang,Dingming; Huang,Yaoyuan; Pan,Qi; Yang,Li; Wu,Junwei

doi:10.3892/ijo.2014.2784

Excision repair cross complementation group 1 is a chemotherapy-tolerating gene in cisplatin-based treatment for non-small cell lung cancer

Authors:
- Shoufeng Wang
- Hong Pan
- Desen Liu
- Naiquan Mao
- Chuantian Zuo
- Li Li
- Tong Xie
- Dingming Huang
- Yaoyuan Huang
- Qi Pan
- Li Yang
- Junwei Wu
View Affiliations

Affiliations: Department of Thoracic Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China
Published online on: November 28, 2014 https://doi.org/10.3892/ijo.2014.2784
Pages: 809-817

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This study aimed to evaluate the biological functions of excision repair cross complementation goup 1 (ERCC1) in cell proliferation, cell cycle, invasion and cisplatin response of non-small cell lung cancer (NSCLC) cells. Firstly, ERCC1 gene was successfully transfected into H1299 cells by gene cloning and transfection techniques. Then, cell proliferation was determined with the cell growth curve and colony-forming assays. Flow cytometry (FCM) was employed to investigate the cell cycle distribution. The ability of cell invasion was estimated by means of Matrigel invasion assays. Response of NSCLC cells to cisplatin was detected utilizing MTT assays, and the intracellular drug concentrations were determined by the high performance liquid chromatography (HPLC) analysis. Expression of the two cell membrane proteins, P-glycoprotein (P-gp) and multidrug resistance-associated protein (MRP), was also evaluated utilizing FCM technique. By contrast, ERCC1 expression in the NSCLC A549 cells was silenced by small interfering RNA (siRNA) through RNAi technique. In addition, the cytotoxic effect of cisplatin on A549 cells was detected by MTT assays. In the present study, the results demonstrated that ERCC1 had no effect on cell proliferation, cell cycle and the ability of invasion, but showed significant impact on cisplatin response of the NSCLC H1299 cells. Furthermore, siRNA-induced suppression of ERCC1 evidently enhanced sensitivity to cisplatin of NSCLC A549 cells. Therefore, it is confirmed that ERCC1 is a chemotherapy-tolerating gene and a promising predictor in tailoring chemotherapy of NSCLC.

View Figures

View References

1	Le Chevalier T: Adjuvant chemotherapy for resectable non-small-cell lung cancer: where is it going? Ann Oncol. 21(Suppl 7): vii196–vii198. 2010. View Article : Google Scholar : PubMed/NCBI
2	Azzoli CG, Park BJ, Pao W, Zakowski M and Kris MG: Molecularly tailored adjuvant chemotherapy for resected non-small cell lung cancer: a time for excitement and equipoise. J Thorac Oncol. 3:84–93. 2008. View Article : Google Scholar : PubMed/NCBI
3	Dziadziuszko R and Hirsch FR: Advances in genomic and proteomic studies of non-small-cell lung cancer: clinical and translational research perspective. Clin Lung Cancer. 9:78–84. 2008. View Article : Google Scholar : PubMed/NCBI
4	Taillade L, Penault-Llorca F, Boulet T, et al: Immunohistochemichal expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small cell lung cancer. Ann Oncol. 18:1043–1050. 2007. View Article : Google Scholar : PubMed/NCBI
5	Toschi L and Cappuzzo F: Impact of biomarkers on non-small cell lung cancer treatment. Target Oncol. 5:5–17. 2010. View Article : Google Scholar : PubMed/NCBI
6	Bowden NA: Nucleotide excision repair: why is it not used to predict response to platinum-based chemotherapy? Cancer Lett. 346:163–171. 2014. View Article : Google Scholar : PubMed/NCBI
7	Simon GR, Ismail-Khan R and Bepler G: Nuclear excision repair-based personalized therapy for non-small cell lung cancer: from hypothesis to reality. Int J Biochem Cell Biol. 39:1318–1328. 2007. View Article : Google Scholar : PubMed/NCBI
8	Rosell R, Lord RV, Taron M and Reguart N: DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer. 38:217–227. 2002. View Article : Google Scholar : PubMed/NCBI
9	Friboulet L, Barrios-Gonzales D, Commo F, et al: Molecular characteristics of ERCC1-negative versus ERCC1-positive tumors in resected NSCLC. Clin Cancer Res. 17:5562–5572. 2011. View Article : Google Scholar : PubMed/NCBI
10	Bepler G: Pharmacogenomics: a reality or still a promise? Lung Cancer. 54(Suppl 2): S3–S7. 2006. View Article : Google Scholar : PubMed/NCBI
11	Custodio A, Mendez M and Provencio M: Targeted therapies for advanced non-small-cell lung cancer: current status and future implications. Cancer Treat Rev. 38:36–53. 2012. View Article : Google Scholar
12	Stewart DJ: Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Crit Rev Oncol Hematol. 75:173–234. 2010. View Article : Google Scholar : PubMed/NCBI
13	Gossage L and Madhusudan S: Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat Rev. 33:565–577. 2007. View Article : Google Scholar : PubMed/NCBI
14	Rosell R, Vergnenegre A, Liu B, et al: Biomarkers in lung oncology. Pulm Pharmacol Ther. 23:508–514. 2010. View Article : Google Scholar : PubMed/NCBI
15	Chen J, Emara N, Solomides C, Parekh H and Simpkins H: Resistance to platinum-based chemotherapy in lung cancer cell lines. Cancer Chemother Pharmacol. 66:1103–1111. 2010. View Article : Google Scholar : PubMed/NCBI
16	Rosell R, Cobo M, Isla D, Camps C and Massuti B: Pharmacogenomics and gemcitabine. Ann Oncol. 17(Suppl 5): v13–v16. 2006. View Article : Google Scholar : PubMed/NCBI
17	O’Brien CP, Taylor SE, O’Leary JJ and Finn SP: Molecular testing in oncology: problems, pitfalls and progress. Lung Cancer. 83:309–315. 2014. View Article : Google Scholar
18	Olaussen KA, Dunant A, Fouret P, et al: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 355:983–991. 2006. View Article : Google Scholar : PubMed/NCBI
19	Takenaka T, Yoshino I, Kouso H, et al: Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer. Int J Cancer. 121:895–900. 2007. View Article : Google Scholar : PubMed/NCBI
20	Tiseo M, Bordi P, Bortesi B, et al: A ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin. Br J Cancer. 108:1695–1703. 2013. View Article : Google Scholar : PubMed/NCBI
21	Rosell R, Cecere F, Santarpia M, Reguart N and Taron M: Predicting the outcome of chemotherapy for lung cancer. Curr Opin Pharmacol. 6:323–331. 2006. View Article : Google Scholar : PubMed/NCBI
22	Ota S, Ishii G, Goto K, et al: Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. Lung Cancer. 64:98–104. 2009. View Article : Google Scholar
23	Wachters FM, Wong LS, Timens W, Kampinga HH and Groen HJ: ERCC1, hRad51 and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy. Lung Cancer. 50:211–219. 2005. View Article : Google Scholar : PubMed/NCBI
24	Filipits M and Pirker R: Predictive markers in the adjuvant therapy of non-small cell lung cancer. Lung Cancer. 74:355–363. 2011. View Article : Google Scholar : PubMed/NCBI
25	Filipits M, Haddad V, Schmid K, et al: Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program. Clin Cancer Res. 13:3892–3898. 2007. View Article : Google Scholar : PubMed/NCBI
26	Voortman J, Goto A, Mendiboure J, et al: MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res. 70:8288–8298. 2010. View Article : Google Scholar : PubMed/NCBI
27	Filipits M, Pirker R, Dunant A, et al: Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program. J Clin Oncol. 25:2735–2740. 2007. View Article : Google Scholar : PubMed/NCBI
28	Pan H, Li L, Zuo CT, Mao NQ, Chen FL, Zhang W and Tang BJ: Relationship between combined multigene detection and response to adjuvant chemotherapy in early-stage non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi. 30:528–531. 2008.PubMed/NCBI
29	Elbashir SM, Lendeckel W and Tuschl T: RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 15:188–200. 2001. View Article : Google Scholar : PubMed/NCBI
30	Jiang J, Liang X, Zhou X, Huang R, Chu Z and Zhan Q: ERCC1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer: a meta-analysis. Mol Biol Rep. 39:6933–6942. 2012. View Article : Google Scholar : PubMed/NCBI
31	Tepeli E, Caner V, Buyukpinarbasili N, Cetin GO, Duzcan F, Elmas L and Bagci G: Expression of ERCC1 and its clinicopathological correlations in non-small cell lung cancer. Mol Biol Rep. 39:335–341. 2012. View Article : Google Scholar
32	Koc E, Caner V, Buyukpinarbasili N, Tepeli E, Turk NS, Ozan Cetin G and Bagci G: The determination of relationship between ‘excision repair cross-complementing group 1’ (ERCC1) gene T19007C and C8092A single nucleotide polymorphisms and clinicopathological parameters in non-small cell lung cancer. Mol Biol Rep. 39:375–380. 2012. View Article : Google Scholar
33	Yang Y and Xian L: The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis. Tumour Biol. 35:2905–2921. 2014. View Article : Google Scholar
34	Friboulet L, Olaussen KA, Pignon JP, et al: ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med. 368:1101–1110. 2013. View Article : Google Scholar : PubMed/NCBI
35	Rabik CA and Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev. 33:9–23. 2007. View Article : Google Scholar :
36	Altaha R, Liang X, Yu JJ and Reed E: Excision repair cross complementing-group 1: gene expression and platinum resistance. Int J Mol Med. 14:959–970. 2004.PubMed/NCBI
37	Chang IY, Kim MH, Kim HB, Lee DY, Kim SH, Kim HY and You HJ: Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin. Biochem Biophys Res Commun. 327:225–233. 2005. View Article : Google Scholar : PubMed/NCBI